Entasis Therapeutics
Gatehouse Park BioHub
35 Gatehouse Drive
Waltham
Massachusetts
02451
United States
Website: http://www.entasistx.com/
Email: rachel.lewis@entasistx.com
67 articles with Entasis Therapeutics
-
Burlingame, CA-based Innoviva is buying all of Waltham, MA-based Entasis Therapeutics' available shares at $2.20 per share. Currently, Innoviva owns about 60% of Entasis’ outstanding shares.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
5/17/2022
Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company presented data highlights from its pivotal Phase 3 ATTACK trial at the American Thoracic Society (ATS) annual conference.
-
Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
4/27/2022
Entasis Therapeutics Holdings Inc. today announced its first quarter 2022 financial results and provided a business update.
-
Recently, antimicrobial resistance has re-emerged in the public limelight as an increasingly severe global health problem.
-
Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update
3/3/2022
Entasis Therapeutics Holdings Inc. today announced full year 2021 financial results and provided a business update.
-
Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.
2/2/2022
Entasis Therapeutics Holdings Inc. today announced that its Board of Directors received a preliminary, non-binding proposal from its majority stockholder Innoviva, Inc. (“Innoviva”) to acquire all of the outstanding equity securities of Entasis that are not currently owned by Innoviva for a per share consideration of $1.80 payable in cash.
-
Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022
1/10/2022
Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022.
-
Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update Management to host a conference call on November 4, 2021 at 8:00am ET
11/4/2021
Entasis Therapeutics Holdings Inc. today announced financial results for the third quarter 2021 and issued a business update for the quarter and recent weeks.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
Biopharma News You've Missed This Week
10/20/2021
More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival. -
Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
10/18/2021
Entasis Therapeutics today announced topline results from its ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacterbaumannii.
-
Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
9/9/2021
Entasis Therapeutics Holdings Inc. announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference.
-
Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections
8/10/2021
Entasis Therapeutics Holdings Inc. announced today that the Company will host a virtual webinar featuring presentations by Infectious Diseases experts David van Duin, M.D., Ph.D.
-
Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum
6/18/2021
Entasis Therapeutics Holdings Inc. today announced multiple presentations at the World Microbe Forum 2021, taking place virtually June 20-24.
-
GSK said the sale of Innovia stock would help GSK invest in other “strategic priorities,” likely those aimed at plans to separate into two main offerings over the next couple of years.
-
Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
5/5/2021
ATTACK Phase 3 topline data readout remains on track for second half of 2021
-
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.
1/26/2021
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the availability of an expanded access program (EAP) for sulbactam-durlobactam or SUL-DUR, an investigational drug, for U.S. patients with Acinetobacter
-
Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference
1/7/2021
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. The Company’s presentation will be available on demand starting Monday, January 11
-
Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium
11/17/2020
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19 th , 2020. The event will consist of 1-on-1 virtual investor meetings. Investors attending the conference virtually who are interested in meeting with C